France’s Saint‑Julien site adds a bioprocess development suite for upstream/downstream scale-up of recombinant proteins, ...

Throughout 2025, drugmakers of all stripes have collectively poured billions of dollars into U.S. manufacturing investments. Many of those projects have centered on later stages of the production ...

SAN DIEGO--(BUSINESS WIRE)--National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced it has raised ...

LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and CDMO services for the full drug product lifecycle, today announced the second phase of its CDMO growth ...

Axplora, a German CDMO that specializes in specialty active pharmaceutical ingredients for small molecules and antibody-drug ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the completion of ...

Cambrex is expanding US and European operations with major investments in Iowa and Milan, boosting API capacity and R and D ...

Scheduled for August 2025 completion, the initial $2-billion phase included construction of a 1-million-sq-ft complex with two drug substance manufacturing buildings, each containing four 20,000-liter ...

BRIDGEWATER, N.J. & NEW YORK--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, and ...

Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is ...